

Proyecto Misión Cáncer – Participación del SERMAS

Dr. Guillermo Velasco –

Servicio de Oncología del Hospital
Universitario 12 de Octubre.

Proyecto CARE1

– Hospital 12 de octubre – FIBHU12O

Call:

Horizon Europe (HORIZON)


Call: HORIZON-MISS-2022-CANCER-01

Project: 101104801 — CARE1

Topic

- HORIZON-MISS-2022-CANCER-01-03 —
- **Pragmatic clinical trials to optimise treatments for patients with refractory cancer**
- Type of action: HORIZON Research and Innovation Actions


INTRODUCTION and rationale of the TRIAL




All these combinations are effective therapy

All show **Overall Survival** benefit over sunitinib


KN 426




CM 9-ER



CLEAR



CM 214



- 1. Motzer R et al. *N Engl J Med*. 2018;387:1277-1290. 2. Rini et al, 2020 3. Motzer et al. *N Engl J Med*. 2021;384:1289-300. 4. Choueiri et al. 2020



CARE1 Overview



This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101104801

1. PROJECT INFORMATION

Grant Agreement number:	101104801
Acronym:	CARE1
Title:	First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma
Framework Programme:	Horizon Europe
Call:	HORIZON-MISS-2022-CANCER-01
Topic:	HORIZON-MISS-2022-CANCER-01-03 - Pragmatic clinical trials to optimise treatments for patients with refractory cancers
Type of Action:	HORIZON Research and Innovation Actions
European officers:	Monika WOZINSKA
Start Date:	01 May 2023
Duration:	60 months
Maximum EC contribution:	€5,577,693.50
Model Grant Agreement:	HE MGA — Multi & Mono - V1.0
Granting Authority:	Agency
Granting Authority Service:	HADEA/A/03

CARE1 Programme Overview



WP1: CARE 1 PCT (Lead IGR)



WP2

**Pathological SOC
implementation and
Pathomic AI**
(Lead CHU Rennes)



WP3

**QoL and
Digital Reported
Outcomes**
(Lead IKCC/Resilience)



WP4

**Cost Optimization:
Health Economics –
Data Extraction**
(UKEssen / IGR)



WP5


**Imaging AI - Blood
Based biomarker**
(SERMAS / QMUL / IGR)



WP6: Communication, Dissemination, Exploitation
(Lead: IGR / IKCC)

WP7: Governance, Management, Data, Ethics
(Lead IGR)


FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA



Ambitions

CARE1 Main assets

Outputs





Engaging in the Cancer Mission



EURICE – European Research and Project Office GmbH

Experts in Collaborative Research & Innovation

Project acronym: COMFORT

Call: HORIZON-HLTH-2022-TOOL-12-two-stage

Topic: HORIZON-HLTH-2022-TOOL-12-01-two-stage

Type of action: HORIZON Research and Innovation

Actions

Granting authority: European Health and Digital Executive Agency

Grant managed through EU Funding & Tenders Portal:
Yes (eGrants)

Project starting date: first day of the month following the entry into force date

Project end date: starting date + months of duration

Project duration: 48 months

